This CMPI PE ratio history page last updated 5/16/2022
Period | Price | GAAP | TTM | PE |
Q1 2022 5/12/2022 | 10.43 | -0.73 | -2.92 | NA | Q4 2021 3/29/2022 | 3.21 | -0.62 | -2.84 | NA | Q3 2021 11/12/2021 | 4.25 | -0.69 | -0.92 | NA | Q2 2021 8/12/2021 | 5.30 | -0.88 | -1.07 | NA | Q1 2021 5/13/2021 | 6.17 | -0.65 | -7.56 | NA | Q4 2020 3/29/2021 | 10.79 | 1.30 | NA | NA | Q3 2020 11/13/2020 | 10.70 | -0.84 | NA | NA | Q2 2020 9/18/2020 | 10.67 | -7.37 | NA | NA |
|
Period | Price | GAAP | Annualized | PE |
Q1 2022 5/12/2022 | 10.43 | -0.73 | -2.92 | NA | Q4 2021 3/29/2022 | 3.21 | -0.62 | -2.48 | NA | Q3 2021 11/12/2021 | 4.25 | -0.69 | -2.76 | NA | Q2 2021 8/12/2021 | 5.30 | -0.88 | -3.52 | NA | Q1 2021 5/13/2021 | 6.17 | -0.65 | -2.60 | NA | Q4 2020 3/29/2021 | 10.79 | 1.30 | 5.20 | 2.1 | Q3 2020 11/13/2020 | 10.70 | -0.84 | -3.36 | NA | Q2 2020 9/18/2020 | 10.67 | -7.37 | -29.48 | NA |
|
On this page we presented the CMPI PE Ratio History information for Checkmate Pharmaceuticals' stock.
The average CMPI PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 2.1. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CMPI PE ratio history based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.
Let's now compare this CMPI PE ratio history result, against the recent PE: when this page was posted on 5/13/2022, the most recent closing price for CMPI had been 10.44, and the most recent quarterly earnings result, annualized, was 5.2. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent CMPI PE on 5/13/2022 based on annualized quarterly EPS was 2.0. Based on CMPI's history, that recent PE is low relative to the historical average, with the recent PE 4.8% lower than the historical average PE across our data set for Checkmate Pharmaceuticals.
For self directed investors doing their due diligence on CMPI or any other given stock, valuation analysis for CMPI
can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can
help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios
justify the current stock market value.
That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate
Checkmate Pharmaceuticals PE ratio history — or the PE history for any stock in our coverage universe.
And in your continued research we hope you will be sure to check out the further links included for
next earnings dates and also historical earnings surprises history for CMPI. Thanks for visiting, and the next
time you need to research CMPI PE Ratio History or the PE ratio history for another stock, we hope our site
will come to mind as your go-to PE ratio history research resource of choice.